The pharmacovigilance market is set to expand significantly, driven by increased clinical trials and pharmaceutical innovations, with a CAGR exceeding 14%.
ESOMAR-certified company Future Market Insights (FMI) has published a report on the global pharmacovigilance market for the forecast period 2021-2031. According to the report, the market is poised to reach new heights, as pharmaceutical companies scramble to introduce new drug candidates for multiple ailments, which will result in an increase in clinical trials. As per FMI’s analysis, the market is expected to register double-digit growth, experiencing an impressive CAGR throughout the forecast period. Historically, the market posted credible gains, surpassing US$ 6 billion in 2020, expanding at a CAGR of over 14%. Growth prospects were further heightened during the COVID-19 pandemic, as the scramble for new treatment approaches is prompting pharmaceutical companies to initiate clinical trials for the same.
To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1107
Prominent pharmaceutical companies are forging long-term partnerships and service agreements with contract research organizations and business processing outsourcing units to enhance existing pharmacovigilance operations by virtue of cost reduction from drug delivery to post-marketing approvals. In April 2021, Thermo Fisher Scientific Inc. announced its plans to acquire Pharmaceutical Product Development (PPD) Inc. for a purchase price of US$ 17.4 billion, which will help enhance the latter’s pharmacovigilance portfolio expansion.
Key Takeaways from FMI’s Pharmacovigilance Market Study
For Information On The Research Approach Used In The Report, Request TOC@ https://www.futuremarketinsights.com/toc/rep-gb-1107
“Rising prevalence of chronic and infectious ailments is prompting multiple pharmaceutical giants to initiate widespread clinical trials for potential drug molecules, generating a highly competitive environment and generating major revenue pools,” says the FMI analyst.
Competitive Landscape
Prominent pharmacovigilance solutions providers are relying on collaborating with prominent biopharmaceutical and pharmaceutical companies to offer their digital solutions to facilitate effective patient care solutions. Also, offering advanced solutions is another prominent strategy. Some prominent faces include F. Hoffmann- La Roche, GlaxoSmithKline Plc., Covance Inc., ICON Plc. and iGATE Corporation among others.
Covance Inc. is a prominent pharmacovigilance solutions providing, offering end-to-end PV services spanning clinical and post-marketing phases from medical contract centers to ICSRs to medical reviews to electronic regulatory submissions. The system helps track weekly, daily and monthly metrics for quality, productivity and efficiency.
In April 2020, ICON Plc. initiated efforts to enhance pharmacovigilance practices, considering the onset of COVID-19. A webinar conducted on this issue by the company called for key pharmaceutical companies to automate their workflows by installing proactive and dedicated intelligence processes, forging detailed business and continuity plans and a virtually globally distributed footprint.
For critical insights on this market, request to ask an expert here @ https://www.futuremarketinsights.com/askus/rep-gb-1107
More Insights on the Global Pharmacovigilance Market
In its latest report, FMI offers an unbiased analysis of the global pharmacovigilance market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of phase of drug development (preclinical studies, phase I, phase II, phase III and phase IV), type of methods (spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring and EHR mining), service type provider (in-house pharmacovigilance and contract outsourcing) and region (North America, Latin America, Europe, Asia-Pacific and Middle East & Africa).
About the Healthcare Division at Future Market Insights
Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here
Explore FMI’s Extensive Coverage on Healthcare Domain
Electronic Stethoscope Market – Global Electronic Stethoscope Market was valued at US$ 170.9 Mn in 2021 and the sales are expected to surpass US$ 259 Mn, increasing by 2.2x between 2022 and 2029
Bone Growth Stimulators Market The global Bone Growth Stimulators Market size is poised to reach US$ 1.8 Bn in 2022.
U.S. Compounding Pharmacies Market U.S. Compounding Pharmacies Market is projected to exceed US$ 4.64 Bn and is expected to grow at over 5.1% CAGR between 2022 and 2028
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition.
Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/
Report: https://www.futuremarketinsights.com/reports/pharmacovigilance-market Press Release Source: https://www.futuremarketinsights.com/press-release/pharmacovigilance-market
The article discusses the growth and future prospects of the pharmacovigilance market.
The market is expected to grow at a CAGR exceeding 14% through 2031.
Increased clinical trials and pharmaceutical innovations are key drivers.
Explore more articles in the Research Reports category
